Serum Metabolomics Identifies Altered Bioenergetics, Signaling Cascades in Parallel with Exposome Markers in Crohn’s Disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD) has stimulated much interest due to its surging incidences and health impacts in the U.S. and worldwide. However, the exact cause of IBD remains incompletely understood, and biomarker is lacking towards early diagnostics and effective therapy assessment. To tackle these, the emerging high-resolution mass spectrometry (HRMS)-based metabolomics shows promise. Here, we conducted a pilot untargeted LC/MS metabolomic profiling in Crohn’s disease, for which serum samples of both active and inactive cases were collected, extracted, and profiled by a state-of-the-art compound identification workflow. Results show a distinct metabolic profile of Crohn’s from control, with most metabolites downregulated. The identified compounds are structurally diverse, pointing to important pathway perturbations ranging from energy metabolism (e.g., β-oxidation of fatty acids) to signaling cascades of lipids (e.g., DHA) and amino acid (e.g., L-tryptophan). Importantly, an integral role of gut microbiota in the pathogenesis of Crohn’s disease is highlighted. Xenobiotics and their biotransformants were widely detected, calling for massive exposomic profiling for future cohort studies as such. This study endorses the analytical capacity of untargeted metabolomics for biomarker development, cohort stratification, and mechanistic interpretation; the findings might be valuable for advancing biomarker research and etiologic inquiry in IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087
The impact of the gut microbiota on human health: an integrative view
Clemente, J. C., Ursell, L. K., Parfrey, L. W., & Knight, R. (2012) · Cell · doi:10.1016/j.cell.2012.01.035 · Cited by 3,710 · cited 1×
“Mounting evidence suggests that intestinal microbiota play a pivotal role in maintaining the health of the bowel [44,45].”
BackgroundIndigenous bacteria from the gut microbiota regulate host serotonin biosynthesis
Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015) · Cell · doi:10.1016/j.cell.2015.02.047 · Cited by 3,614 · cited 1×
“A recent landmark study on the metabolism of gut-derived 5-HT delineates how spore-forming bacteria (Sp) regulates host peripheral 5-HT levels, with profound effects on host physiology, gut motility, and hemostasis [22].”
BackgroundWild, C. P. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0456 · Cited by 2,562 · cited 1×
“Indeed, the field of exposomics is only at its budding stages in epidemiological investigation, and much needs to be done to enable sensitive, comprehensive and real-time exposure characterization for unravelling causal factors of IBD and of other complex chronic diseases [34,35].”
BackgroundRole of the gut microbiota in immunity and inflammatory disease
Kamada, N., Seo, S.-U., Chen, G. Y., & Núñez, G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3430 · Cited by 2,256 · cited 1×
“Dysbiosis of gut microbes has been shown to induce unsolicited immune responses, destroy the integrity of intestinal epithelial barrier (IEB), and spark systemic inflammation, resulting in diseases spanning metabolic syndrome [46], autoimmune diseases [47], and cancer [48].”
BackgroundMetabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5
Vijay-Kumar, M., Aitken, J. D., Carvalho, F. A., Cullender, T. C., Mwangi, S., Srinivasan, S., Sitaraman, S. V., Knight, R., Ley, R. E., & Gewirtz, A. T. (2010) · Science · doi:10.1126/science.1179721 · Cited by 2,068
Venkatesh, M., Mukherjee, S., Wang, H., Li, H., Sun, K., Benechet, A. P., Qiu, Z., Maher, L., Redinbo, M. R., Phillips, R. S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.014 · Cited by 1,066
Sphingosine-1-phosphate signaling and its role in disease
Maceyka, M., Harikumar, K. B., Milstien, S., & Spiegel, S. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.003 · Cited by 1,039 · cited 1×
“S1P (d16:1) is a derivative of S1P, with the latter playing critical regulatory roles in various physiological and pathogenetic contexts, and more recently, in inflammatory responses [42].”
BackgroundFrom gut dysbiosis to altered brain function and mental illness: mechanisms and pathways
Rogers, G. B., Keating, D. J., Young, R. L., Wong, M.-L., Licinio, J., & Wesselingh, S. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.50 · Cited by 969 · cited 1×
“Since intestinal enterochromaffin cells (ECs)-derived 5-HT (accounting for 90% in human body) does not cross blood-brain barrier (BBB), the amount of 5-HT in the brain solely relies on in situ central nervous system (CNS) synthesis by serotonergic neurons [57].”
BackgroundMichielan, A., & D’Incà, R. (2015) · Mediators of Inflammation · doi:10.1155/2015/628157 · Cited by 709 · cited 1×
“The increase is likely due to elevated intake of caffeine, a compromise in their metabolizing capacity, and a leaky gut in the diseased that allow intestinal caffeine metabolites to come across and reach the circulation system [66].”
BackgroundDepression and anxiety in inflammatory bowel disease: A review of comorbidity and management
Graff, L. A., Walker, J. R., & Bernstein, C. N. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20873 · Cited by 586 · cited 1×
“This may explain for depression, anxiety and many other comorbid mental symptoms reported in Crohn’s cases [24].”
BackgroundThe blood exposome and its role in discovering causes of disease
Rappaport, S. M., Barupal, D. K., Wishart, D., Vineis, P., & Scalbert, A. (2014) · Environmental Health Perspectives · doi:10.1289/ehp.1308015 · Cited by 393 · cited 1×
“Indeed, the field of exposomics is only at its budding stages in epidemiological investigation, and much needs to be done to enable sensitive, comprehensive and real-time exposure characterization for unravelling causal factors of IBD and of other complex chronic diseases [34,35].”
BackgroundHold, G. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i5.1192 · Cited by 365
Role of the microbiota in inflammatory bowel diseases
Nagalingam, N. A., & Lynch, S. V. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21866 · Cited by 315
The unusual amino acid L-ergothioneine is a physiologic cytoprotectant
Paul, B. D., & Snyder, S. H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.163 · Cited by 304
An integrative view of microbiome-host interactions in inflammatory bowel diseases
Wlodarska, M., Kostic, A. D., & Xavier, R. J. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.04.008 · Cited by 287
Yokoyama, S., Watanabe, T., Murao, K., Ishikura, H., Yamaizumi, Z., Nishimura, S., & Miyazawa, T. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.15.4905 · Cited by 271 · cited 2×
“methylation of 5-methyluridine that is likely a result of DNA methylation, a common epigenetic modification scheme [36]; the whole process is involved in codon recognition by tRNA [37].”
BackgroundGene Knockout and Metabolome Analysis of Carnitine/Organic Cation Transporter OCTN1
Kato, Y., Kubo, Y., Iwata, D., Kato, S., Sudo, T., Sugiura, T., Kagaya, T., Wakayama, T., Hirayama, A., Sugimoto, M., et al. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0076-z · Cited by 206
Shimizu, T., Masuo, Y., Takahashi, S., Nakamichi, N., & Kato, Y. (2015) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2015.02.003 · Cited by 45
Cited by
Gut microbiota-derived metabolites as key actors in inflammatory bowel disease
Lavelle, A., & Sokol, H. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0258-z · Cited by 2,015
The Gut Microbiome and Inflammatory Bowel Diseases
Shan, Y., Lee, M., & Chang, E. B. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-021020 · Cited by 413
The biology of ergothioneine, an antioxidant nutraceutical
Borodina, I., Kenny, L. C., McCarthy, C. M., Paramasivan, K., Pretorius, E., Roberts, T. J., van der Hoek, S. A., & Kell, D. B. (2020) · Nutrition Research Reviews · doi:10.1017/s0954422419000301 · Cited by 296
Metabolomic analysis in inflammatory bowel disease: A systematic review
Gallagher, K., Catesson, A., Griffin, J. L., Holmes, E., & Williams, H. R. T. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjaa227 · Cited by 133
Metadata
- Authors
- Lai, Y., Xue, J., Liu, C.-W., Gao, B., Chi, L., Tu, P., Lu, K., & Ru, H.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2019-01-27
- Volume
- 24
- Issue
- 3
- Pages
- 449
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2912249416
- Cited by
- 80
- References
- 19
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.